Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > Still up 10% on the day..
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(150)
•••
Comment by BehStreet on Jun 04, 2020 3:53pm
112 Views
Post# 31113364

RE:RE:Still up 10% on the day..

RE:RE:Still up 10% on the day..SMH..

NightHawk1987 wrote: 2 or 3 sentences in... I have to stop you. That is NOT how penny stocks, or especially bio pharmaceuticals work. It's not a wait 2 weeks and watch the price increase. Lol no. Its pump and dump. Pump the news and dump. My personal opinion, management screwed up again, by halting the stock. BEFORE OPENING BELL?!! That only works ONE time. Everyone is now savvy and weary. Put out a news release post or pre market. Simple. Salvation is what makes money. They scared off investors that had been loyal, yet abused, for months. BIG MISTAKE. now we are FORCED to wait for data. The market has spoken. Imo there is nothing more they can do. They have broken the relationship with investors, and for an unknown reason to me, have not grabbed the attention of the overall covid market.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities